Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
CD388 Injection
COMBINATION_PRODUCT
3 trials
Sponsors
Cidara Therapeutics Inc.
, Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Conditions
Healthy
Influenza
Phase 1
Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects
Completed
NCT05285137
Cidara Therapeutics Inc.
Healthy
Start: 2022-03-14
End: 2023-10-27
Updated: 2025-02-27
Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects
Completed
NCT05619536
Cidara Therapeutics Inc.
Healthy
Start: 2022-10-18
End: 2023-07-14
Updated: 2024-10-01
Phase 2
Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications
Completed
NCT06609460
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Influenza
Start: 2024-09-20
End: 2025-10-09
Updated: 2026-06-18
Related Papers
2116. Efficacy of CD388, a Novel Drug Fc-Conjugate (DFC), is Driven by the Small Molecule Neuraminidase Inhibitor (NAI)
Open Forum Infectious Diseases
2023-11-27